Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Activist investors dog Bristol-Myers

by Ann M. Thayer
February 27, 2017 | A version of this story appeared in Volume 95, Issue 9

Bristol-Myers Squibb has become the target of activist investors because of lowered earnings expectations, setbacks in immuno-​oncology, and a plummeting stock price. After discussions with the hedge fund Jana Partners, BMS has agreed to add three independent board members and repurchase about $2 billion worth of its stock, or about 2% of its outstanding shares. Jana owns less than 1% of the drug company. News reports indicate that investor Carl Icahn has taken a stake in BMS as well. Together, the developments raise questions about whether the drug company will become a takeover target.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.